with PCR. We felt that clinicians could not be satisfied with a test that failed to diagnose C. difficile infection in >40% of cases. Although, on the basis of recommendations developed early in the EIA era, clinicians often send multiple samples from an individual patient, we only study 1 specimen in any given 7-day period [3] ; thus, the increased expense for PCR reagents is partially mitigated by the elimination of repeated testing. The suggestion that samples first be tested for glutamate dehydrogenase and that positive samples be further studied by PCR involves 2 steps, takes additional time (which translates into problems in clinical management and isolation of patients [4] ), and has been shown to provide false-negative results [5, 6] . As a result, we, along with others [7] , have chosen to work exclusively with PCR as the diagnostic test for C. difficile infection. 
